Cutting hundreds of products in the US, reallocating commercial resources to the most responsive brands around the world, creating a network of centers of excellence and consolidating production capacity are among the measures included in a wide-ranging reform program that Mylan is undertaking as it prepares to merge midway through next year with Pfizer’s Upjohn off-patent brands unit to form a company that will be called Viatris.
Mylan Reforms As It Prepares To Become Viatris
Viatris Chosen As Name For Merged Entity
Mylan is pushing ahead with reforms that include wide-ranging product rationalization in the US, refocusing its commercial resources and cutting development and manufacturing costs. These reforms are intended to run prior to and concurrently with the group’s merger with Pfizer’s Upjohn unit to form Viatris.
More from Manufacturing
More from Business
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
• By
Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.